The two public companies that will emerge from NeXstar's proposed spin-off of its drug discovery assets will look quite similar to the two public companies that merged to create NXTR four years ago.

NeXstar was created through the 1994 merger of NeXagen and Vestar. NeXagen brought oligonucleotide drug discovery technology to the table, while Vestar brought AmBisome lipid amphotericin B and DaunoXome lipid daunorubicin (see BioCentury Nov. 4, 1994).